Drugs

Dec 24, 2024, 14:29

Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma

Laura Bukavina, Urologic Oncologist at Cleveland Clinic Urology, shared a post on X:

“Advanced urothelial carcinoma patients with TSC1 mutations show higher response rates to EV monotherapy (87% vs. 51%), while presence of CDKN2A/B is neg associated with PFS (4.6 vs. 6 ) mo. (Nectin4 is not available).”

Enfortumab

Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data

Authors: Tanya Jindal et al.

Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma

advanced urothelial carcinoma Ajjai Alva Ali Raza Khaki. Amanda Nizam Arnab Basu Cameron Pywell cancer Charles Nguyen Christopher Hoimes Cindy Jiang Deepak Kilari Dimitra Bakaloudi Dory Freeman Emily Lemke Hamid Emamekhoo Joaquim Bellmunt Laura Bukavina Matthew Davidsohn Matthew I. Milowsky Matthew T Campbell Mehmet A Bilen Michael Glover Nancy B. Davis Omar Alhalabi OncoDaily Oncology Pedro C Barata Petros Grivas Rafee Talukder Rohit Bose Sean Evans Shilpa Gupta Sumit A. Shah Tanya Jindal Vadim S Koshkin Woogwang Sim Yousef Zakharia

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage